Showing 15 posts of 64 posts found.

New FDA Commissioner reveals strategy to drive down drug prices

May 26, 2017
Manufacturing and Production, Sales and Marketing FDA, Scott Gottlieb, Trump, pricing

Deregulation, faster access and cheaper drug prices very quickly became the rallying cry for the Trump administration in the life …


Sanofi joins growing list of companies making pricing commitments

May 10, 2017
Medical Communications, Research and Development Sanofi, pricing, transparency

Sanofi has entered an ever-growing list of pharmaceutical companies that are pledging to limit the levels of their price increases …


Mylan hit with fresh lawsuit over EpiPen pricing

April 4, 2017
Manufacturing and Production, Sales and Marketing Mylan, epipen, pricing

Just as it faces worldwide reports that over 80,000 of its EpiPens do not function properly and as the FDA …


Vermont senators call for restraints on “beautiful” pharma advertising

March 6, 2017
Manufacturing and Production, Sales and Marketing Bernie Sanders, Vermont, pricing

Bernie Sanders is yet again leading the charge against US pharma as Vermont senators have rallied against advertising and marketing …


Antitrust investigation into Mylan begins over EpiPen

January 31, 2017
Research and Development, Sales and Marketing Mylan, pricing

The Federal Trade Commission has submitted a request to Mylan for information as part of a preliminary investigation into whether …


India’s NPPA slashes essential drug prices by up to 50%

January 26, 2017
Sales and Marketing India, nppa, pricing

India’s governmental regulatory agency, the National Pharmaceutical Pricing Authority (NPPA), has addressed the pricing of 33 medicines including antibiotics and …


Seven pharma trends for 2017

December 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing

What will be the key industry trends in 2017?Industry uncertaintyPerhaps the biggest hallmark of 2016-going-into-2017 is the sense of hesitation …


GSK emerges top of the pile for improving access to medicine

November 14, 2016
Medical Communications, Sales and Marketing Access to Medicine Index, GSK, market access, pricing

GlaxoSmithKline, the British drugmaker, has topped the overall ranking of the Access to Medicine Index, which ranks 20 top pharmaceutical …


Valeant announces new patient access and pricing committee; vows to correct past “mistakes”

May 6, 2016
Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing

Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …


Two billion people still lack medicines access. Is the industry doing enough?

December 22, 2015
Manufacturing and Production Access to Medicine Foundation, Access to Medicine Index, affordability, market access, medicines access, pricing

“We have a mission to encourage the pharmaceutical industry in improving access to medicine for the two billion people who …

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015
Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …

WHO: New measures needed to reduce high drug costs

March 26, 2015
Research and Development, Sales and Marketing Europe, WHO, pricing, transparency, world health organization

New approaches to drug pricing and reimbursement are needed to make sure pharma provides access to new medicines, according to …

NHS image

Government gets £74m rebate from pharma

June 30, 2014
Sales and Marketing ABPI, Hunt, NHS, PPRS, VBP, emms, pricing

The UK government has received a £74 million refund from the pharma industry after it was deemed to have spent …

Latest content